Jim Tananbaum of Foresite Capital joins Nick to discuss From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction. In this episode we cover:

Data Science and Investment Approach
Investment Practices and Market Conditions
China's Role in Biotech and Regulatory Considerations
Impact of AI on Biotech and Healthcare
Healthcare Adoption of AI and Preventive Measures
Payers and Insurance Companies' Role
Lessons from Successful Investments
Generating Liquidity in a Sluggish Market
Future of GLP-1 Agonists

Guest Links:

The host of The Full Ratchet is Nick Moran of New Stack Ventures, a venture capital firm committed to investing in founders outside of the Bay Area.

We’re proud to partner with Ramp, the modern finance automation platform. Book a demo and get $150—no strings attached.

Want to keep up to date with The Full Ratchet? Follow us on social. You can learn more about New Stack Ventures by visiting our LinkedIn and Twitter.

493. From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction (Jim Tananbaum)

The Full Ratchet (TFR): Venture Capital and Startup Investing Demystified

493. From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction (Jim Tananbaum)